Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 14 | 2025 | 53 | 3.620 |
Why?
|
| Osteosarcoma | 7 | 2022 | 53 | 2.710 |
Why?
|
| Bone Neoplasms | 5 | 2022 | 115 | 2.290 |
Why?
|
| Dogs | 22 | 2025 | 314 | 1.450 |
Why?
|
| Antineoplastic Agents | 8 | 2019 | 628 | 1.250 |
Why?
|
| Doxorubicin | 3 | 2024 | 97 | 0.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2025 | 65 | 0.770 |
Why?
|
| Pyrroles | 3 | 2016 | 44 | 0.730 |
Why?
|
| Indoles | 3 | 2016 | 106 | 0.710 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 29 | 0.650 |
Why?
|
| Dystrophin | 1 | 2019 | 31 | 0.640 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 10 | 0.600 |
Why?
|
| Neoplasms | 5 | 2023 | 1231 | 0.590 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 50 | 0.580 |
Why?
|
| Mutation | 3 | 2025 | 2455 | 0.510 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 347 | 0.510 |
Why?
|
| Splenic Neoplasms | 1 | 2015 | 8 | 0.490 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 23 | 0.480 |
Why?
|
| Animals | 23 | 2025 | 19642 | 0.470 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 67 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 31 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2019 | 120 | 0.280 |
Why?
|
| Carboplatin | 2 | 2019 | 40 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 836 | 0.260 |
Why?
|
| Genomics | 3 | 2025 | 319 | 0.260 |
Why?
|
| DNA Copy Number Variations | 2 | 2025 | 65 | 0.260 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 1368 | 0.250 |
Why?
|
| Whole Genome Sequencing | 2 | 2025 | 63 | 0.220 |
Why?
|
| Acrylamides | 2 | 2023 | 15 | 0.210 |
Why?
|
| Cell Proliferation | 3 | 2022 | 941 | 0.200 |
Why?
|
| Histones | 1 | 2025 | 456 | 0.190 |
Why?
|
| Gene Deletion | 1 | 2022 | 293 | 0.180 |
Why?
|
| Transcriptome | 1 | 2023 | 339 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 355 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 805 | 0.160 |
Why?
|
| Apoptosis | 2 | 2022 | 1033 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2020 | 89 | 0.160 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hydrazines | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2019 | 131 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 2049 | 0.150 |
Why?
|
| Male | 11 | 2025 | 27760 | 0.150 |
Why?
|
| Female | 12 | 2025 | 30736 | 0.150 |
Why?
|
| Cell Line | 1 | 2022 | 1983 | 0.150 |
Why?
|
| Lymphoma | 1 | 2018 | 99 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 64 | 0.140 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 11 | 0.140 |
Why?
|
| Nanotubes | 1 | 2017 | 23 | 0.140 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 18 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2017 | 16 | 0.140 |
Why?
|
| Phototherapy | 1 | 2017 | 34 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2017 | 31 | 0.140 |
Why?
|
| Vinblastine | 1 | 2016 | 18 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5280 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 179 | 0.140 |
Why?
|
| Pubic Bone | 1 | 2016 | 1 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 6 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2016 | 14 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 28 | 0.130 |
Why?
|
| Sacrum | 1 | 2016 | 24 | 0.130 |
Why?
|
| Pyrazines | 1 | 2016 | 33 | 0.130 |
Why?
|
| Benzamides | 1 | 2016 | 63 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 71 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 118 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 13 | 0.120 |
Why?
|
| Tramadol | 1 | 2015 | 16 | 0.120 |
Why?
|
| Piroxicam | 1 | 2015 | 3 | 0.120 |
Why?
|
| Animals, Newborn | 1 | 2015 | 230 | 0.120 |
Why?
|
| Gold | 1 | 2017 | 225 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 170 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 75 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 194 | 0.120 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 141 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 583 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2092 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 397 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2017 | 883 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2016 | 1471 | 0.080 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 550 | 0.070 |
Why?
|
| Anorexia | 2 | 2018 | 6 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 178 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 451 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 228 | 0.060 |
Why?
|
| Diarrhea | 2 | 2016 | 75 | 0.060 |
Why?
|
| Cell Survival | 2 | 2017 | 559 | 0.060 |
Why?
|
| Humans | 7 | 2023 | 59395 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 914 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2024 | 14 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2023 | 57 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 3065 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2023 | 228 | 0.050 |
Why?
|
| Mice | 3 | 2018 | 10286 | 0.040 |
Why?
|
| Triazoles | 1 | 2018 | 51 | 0.040 |
Why?
|
| Oncogenes | 1 | 2018 | 66 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2018 | 108 | 0.040 |
Why?
|
| Proteolysis | 1 | 2018 | 136 | 0.040 |
Why?
|
| Tumor Protein p73 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lethargy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mast Cells | 1 | 2016 | 41 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 2016 | 13 | 0.030 |
Why?
|
| Pelvic Floor | 1 | 2016 | 10 | 0.030 |
Why?
|
| Rectal Diseases | 1 | 2016 | 27 | 0.030 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2016 | 47 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 87 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 99 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 89 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 192 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 284 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 194 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 248 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 137 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2015 | 2 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 133 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2016 | 194 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 513 | 0.030 |
Why?
|
| Neutropenia | 1 | 2015 | 62 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 197 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 477 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 289 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 486 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 396 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2015 | 327 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 263 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 474 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 202 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 912 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 402 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 590 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1557 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 858 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 482 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1506 | 0.020 |
Why?
|